IRIDEX ONBOARD THE ORBIS FLYING EYE HOSPITAL
Flying Eye Hospital staff are now ready to use the IQ532 Laser System and the 810nm OcuLight SLx
Mountain View Calif., September 19, 2016— IRIDEX Corporation (Nasdaq: IRIX) is pleased to announce the completion of training on the IQ 532 Laser System and an 810 nm OcuLight SLx for the permanent staff of the Orbis Flying Eye Hospital. Both the Iridex 810nm OcuLight SLx and the IQ 532 are multifunctional lasers that can be used to perform continuous-wave and MicroPulse procedures to treat retina disorders and glaucoma.
Approximately 285 million people worldwide are visually impaired, but 80% are blinded by preventable and treatable conditions including cataract and glaucoma. Orbis seeks to decrease those numbers by creating a fully equipped hospital onboard an airplane, allowing doctors trained in the latest ophthalmic techniques to bring their surgical knowledge and skills to doctors in developing countries though hands-on training and lectures.
Dr. Jonathan Lord, MBBS, FRCA, Global Medical Director of Orbis, states, “The Flying Eye Hospital shares skills, resources and knowledge required to deliver accessible, quality eye care to those with the least resources. It is a strategic tool within our training efforts to build a sustainable healthcare system in the countries we visit and partner with. We are grateful for our partnerships with companies like Iridex that provide equipment and training for us to disseminate around the world.”
Orbis focuses on treating and preventing avoidable blindness including cataract, glaucoma and refractive error. The physician on the Flying Eye Hospital performs approximately seven surgeries per day, training local physicians. Iridex lasers can be used to treat both glaucoma and retinal diseases, providing alternatives to daily drop regimens that have low compliance rates and complicated surgeries that need significant follow-up.
“Iridex has a long-standing commitment to saving sight worldwide for those patients afflicted by glaucoma and retina disease. Orbis is a unique and exceptional organization focused on sustainable change within the global healthcare community, and we are excited our laser solutions are a part of their mission,” said Tim Buckley, VP of Global Sales & Marketing at Iridex Corp.
ABOUT ORBIS
Orbis is a leading global non-governmental organization that has been a pioneer in the prevention and treatment of blindness for over 30 years. Orbis transforms lives by delivering the skills, resources and knowledge needed to deliver accessible quality eye care. Working in collaboration with local partners including hospitals, universities, government agencies and ministries of health, Orbis provides hands-on ophthalmology training, strengthens healthcare infrastructure and advocates for the prioritization of eye health on public health agendas. Orbis operates the world’s only Flying Eye Hospital, a fully accredited ophthalmic teaching hospital on board an MD-10 aircraft. To learn more about Orbis and to get involved, please visit Orbis.org.
First Flying Eye Hospital program, on board the MD-10, in Shenyang, China Orbis International has been invited by the Health & Family Planning Commission of Shenyang Municipality to conduct a three-week regional ophthalmic training program in Shenyang, China. Hosted by the leading Hu University Eye Hospital (HUEH), the training program is scheduled from September 5 – 23, 2016, aiming to strengthen the skills and capacity of eye care professionals in Liaoning region. The program is co-sponsored by FedEx and Alcon; this is the first training program of our new, third-generation Flying Eye Hospital (FEH), which was launched in June this year.
The new, state-of- the-art Flying Eye Hospital will support an ongoing “Shenyang Training for Prevention of Blindness” project implemented by Orbis North Asia and HUEH. In fact, they are celebrating a 12-year partnership of blindness prevention works in the region this year.
About IRIDEX
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the IRIDEX website at http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company's patents and other intellectual property rights, the Company's patent applications and the issuance of any patents to the Company based upon such applications, the relevance of the Company's patents and other intellectual property rights to the Company's current and future product portfolio, the protectability of, and results of any future challenges to, the Company's intellectual property rights, the Company's products, including the TxCell™ Scanning Laser Delivery System and MicroPulse® technology, future demand and order levels for the Company's products, the adoption and effect of Company products on its results, the markets in which the Company operates, usage and efficacy of the Company's products, future financial results, and the Company's strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2015, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.